IDEAYA Biosciences, Inc. IDYA
30.84 USD -1.52 (-4.70%)
Nov 5, 2026, 3:24 PM EST
30.70 Day range 32.56
26.81 52-week range 42.68
- YTD
- -10.79%
- 1 year
- +3.98%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 51.54 +67.1% upside
Now 30.84
- Target (low)
- 31.00
- Target (mean)
- 51.54
- Target (high)
- 65.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 16
- 2 months ago 14
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.32 | -1.47 – -1.23 | -0.94 | -40.4% | 19.72M | +81.3% | 7 |
| Next quarter | -1.21 | -1.41 – -1.04 | -1.11 | -9.3% | 11.98M | +82.6% | 6 |
| Current year | -4.91 | -5.05 – -4.79 | -1.28 | -283.6% | 32.15M | -85.3% | 6 |
| Next year | -4.08 | -5.43 – -1.78 | -4.91 | +16.8% | 128.93M | +301.1% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 4, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Nov 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Nov 4, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 14, 2026 | Stifel | Initiated | — | Buy |
| Sep 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 1, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 5, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 12, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 7, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Apr 14, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 31, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 19, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 18, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 18, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Feb 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 6, 2026 | Truist Securities | Maintained | Buy | Buy |
| Nov 24, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 11, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 23, 2025 | JP Morgan | Maintained | Overweight | Overweight |
